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Abstract: Pharmacogenomics is a field with origins in the study of monogenic variations in drug metabolism in the 
1950s. Perhaps because of these historical underpinnings, there has been an intensive investigation of 'hepatic 
pharmacogenes' such as CYP450s and liver drug metabolism using pharmacogenomics approaches over the past five 
decades. Surprisingly, kidney pathophysiology, attendant diseases and treatment outcomes have been vastly under-studied 
and under-theorized despite their central importance in maintenance of health, susceptibility to disease and rational 
personalized therapeutics. Indeed, chronic kidney disease (CKD) represents an increasing public health burden worldwide, 
both in developed and developing countries. Patients with CKD suffer from high cardiovascular morbidity and mortality, 
which is mainly attributable to cardiovascular events before reaching end-stage renal disease. In this paper, we focus our 
analyses on renal function before end-stage renal disease, as seen through the lens of pharmacogenomics and human 
genomic variation. We herein synthesize the recent evidence linking selected Very Important Pharmacogenes (VIP) to 
renal function, blood pressure and salt-sensitivity in humans, and ways in which these insights might inform rational 
personalized therapeutics. Notably, we highlight and present the rationale for three applications that we consider as 
important and actionable therapeutic and preventive focus areas in renal pharmacogenomics: 1) ACE inhibitors, as a 
confirmed application, 2) VDR agonists, as a promising application, and 3) moderate dietary salt intake, as a suggested 
novel application. Additionally, we emphasize the putative contributions of gene-environment interactions, discuss the 
implications of these findings to treat and prevent hypertension and CKD. Finally, we conclude with a strategic agenda 
and vision required to accelerate advances in this under-studied field of renal pharmacogenomics with vast significance 
for global public health.  
Keywords: ACE inhibitors, blood pressure, chronic kidney disease, pharmacogenomics genes, renal function, salt intake, VDR 
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1. INTRODUCTION 
 Chronic kidney disease (CKD) represents an increasing 
public health burden [1]. CKD prevalence in adults varies 
from 5% to 16% worldwide [2-6]. CKD is highly prevalent 
in western countries [3] as well as in Asia [7, 8]. 
Epidemiological data in certain countries such as India are 
sparse and the burden of CKD is difficult to evaluate [9]. 
CKD is defined as estimated glomerular filtration rate 
(eGFR) < 60 ml/min/1.73m
2
 or urinary albumin-to-creatinine 
ratio (UACR) > 30 mg/g [1]. CKD and UACR are associated 
with higher all-cause mortality, also in older people [10]. A 
large collaborative meta-analysis including longitudinal data 
on more than 100,000 participants found that eGFR below 
75 ml/min/1.73m
2
 and an UACR above 5 mg/g started to be 
associated with all-cause and cardiovascular mortality, 
independently of each other [11]. CKD patients suffer from 
high cardiovascular morbidity and mortality, which is mainly  
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attributable to cardiovascular events before reaching end-
stage renal disease (ESRD) [12-15].  
 The kidney is a key organ for the balance of many 
endogenous and exogenous compounds including drugs. 
Hence, the kidney is responsible for the excretion of 
numerous drugs and their metabolites. Some substances need 
to be actively maintained in the body (e.g., glucose, amino 
acids, etc.), while others need to be eliminated (e.g. urea, 
uric acid, exogenous compounds, etc.). When managing 
these various processes, the kidney may be damaged by the 
action of nephrotoxic substances (either endogenous or 
exogenous).  
 Several areas firmly link pharmacogenomics to the 
kidney as listed in Table 1. We herein focus on the third 
context, namely the role of proteins involved in the 
metabolism and transport of drugs in renal function and 
blood pressure control to select the top three pharmaco-
genomic applications to better understand renal patho- 
physiology in cardiovascular medicine. This review does not 
cover the use of pharmacogenomics in the field of renal 
transplantation as this area has been extensively covered in 
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recent years [16-20]. Similarly, we do not explore the link 
between pharmacogenomics and acute renal failure. 
 There is large inter-individual variability in drug 
response [21]. Such variability has been shown to be 
heritable [22, 23]. It is likely that the inter-individual 
variability in response to other xenobiotics and to endo- 
genous compounds is similarly large and also heritable. 
Selected genetic polymorphisms located within genes 
encoding drug-metabolizing enzymes (e.g., CYP3A5) or drug 
transporters (e.g., ABCB1) are considered to be functional. 
The strength of the association between genetic variability 
and function of the corresponding protein greatly varies 
across pharmacogenes. Genetic variants of the CYP1A2 
gene, for instance, show little association with CYP1A2 
enzymatic activity [24], whereas CYP3A5 genotype is an 
excellent predictor of CYP3A5 phenotype [25].  
 According to the Pharmacogenomics Knowledge 
Database [26, 27], 44 genes are classified as being very 
important pharmacogenes (VIP). In addition to the classical 
hypertension and renal function candidate gene ACE, recent 
evidence suggests that several of these genes may play a role 
in the physiological control of renal function and blood 
pressure, even in the absence of drug treatment [28-31]. The 
VIP genes we selected in this paper belong to four 
categories: a) phase I enzymes (CYP1A2 and CYP3A5), b) 
transporters (ABCB1), c) nuclear receptors (VDR and PXR) 
and d) others (ACE, MTHFR). These genes are highly 
interconnected as illustrated in Fig. (1), which synthesize the 
crossroads between selected nuclear receptors, drug 
metabolizing enzymes and transporters as well as other 
pharmacogenes for their effects on renal function and 
diseases, in part via renal sodium handling.  
 The kidney plays a major role in blood pressure control 
and hypertension is considered as an important risk factor for 
nephropathy. As a consequence, these VIP genes represent 
important candidates for CKD and ESRD. In this review, we 
would like to highlight the complex interplay between inter-
individual variability in response to drug treatment, inter-
individual variability in the metabolism and transport of 
endogenous substances as well as inter-individual variability 
in the response to environmental factors (e.g., dietary salt 
intake) for their effects on renal function and blood pressure. 
The link between hypertension and kidney disease is 
complex because it is bidirectional. Reduced renal function 
is associated with raised blood pressure and hypertension is a 
risk factor for nephropathy. From a genetics perspective, this 
complexity is illustrated by the limited overlap between 
blood pressure and renal function loci (and candidate genes) 
identified so far in large scale genome-wide association 
studies. For instance, in the recently published genome-wide 
meta-analysis of the International Consortium on Blood 
Pressure genetics, a genetic score based on 29 variants 
associated with blood pressure was associated with stroke 
and heart disease, but not with renal function or CKD [32]. 
 Blood pressure levels aggregate in families and are 
heritable. This suggests that genes play a role in blood 
pressure control. As a result of intra-individual blood 
pressure variability, heritability estimates are usually 
stronger and more significant when multiple measurements 
are averaged, such as is the case for ambulatory blood 
pressure monitoring [33]. When the average of only two 
measurements is taken, the blood pressure phenotype is 
noisier and very large sample sizes are needed to detect 
small genetic effect sizes. One way to ensure that a specific 
genetic association with blood pressure is not a false positive 
is to replicate results across independent samples as was 
done in large-scale genome-wide meta-analyses. There is no 
consensus on how to define salt-sensitivity of blood pressure 
[34], but one usually considers that a person is salt-sensitive 
whenever her/his blood pressure increase by 5% to 10% in 
response to a large increase in dietary salt intake (e.g., 200 
mmol Na/d versus 20 mmol Na/d) [34]. 
 This paper brings together a critical synthesis of recent 
evidence linking selected VIP genes, namely ABCB1, ACE, 
CYP1A2, CYP3A5, MTHFR, PXR and VDR, to (1) renal 
function, (2) blood pressure and (3) salt sensitivity focusing 
on, though not restricting to, results in humans (Table 2). 
Notably, we highlight and present the rationale for three 
leading applications that we consider as important and 
actionable therapeutic and preventive focus areas in renal 
pharmacogenomics: 1) ACE inhibitors, as a confirmed 
application, 2) VDR agonists, as a promising application, 
and 3) moderate dietary salt intake, as a suggested novel 
application. In the course of this discussion, we underscore 
the potential role of gene-environment interactions, discuss 
the implications of these findings to treat and prevent 
hypertension and CKD and bring up new ideas for research 
in the coming decade to accelerate this under-studied and yet 
critical subfield of pharmacogenomics on the path to 
personalized medicine.  
Table 1. Interface Between Pharmacogenomics and the Kidney 
Context for Research Focus Significance 
1. Drugs used to treat renal pathologies acting on a 
protein encoded by a pharmacogene 
Drugs Inter-individual variability in drug response 
2. Nephrotoxic drugs Drugs Inter-individual variability in nephrotoxicity 
3. Proteins involved in the metabolism and transport 
of drugs and renal function and blood pressure 
Endogenous compounds Inter-individual differences in the progression of chronic 
kidney disease (even in the absence of drug treatment) 
4. Interactions between endogenous and exogenous 
compounds 
Endogenous and exogenous 
(drugs + others) compounds 
Large inter-individual variability in age-related renal 
function decline 
Renal Function and Pharmacogenomics Current Pharmacogenomics and Personalized Medicine, 2011, Vol. 9, No. 4    301 
2. SELECTED VIP GENES: BLOOD PRESSURE; 
SALT-SENSITIVITY AND RENAL FUNCTION 
2.1. Phase I Enzymes 
2.1.1. CYP1A2 Gene  
 The CYP1A2 gene lies on chromosome 15q24.1, shares a 
5’-flanking region with CYP1A1 and features seven exons 
[35]. CYP1A2 encodes a member of the cytochrome P450 
superfamily enzyme, the CYP1A2 enzyme. CYP1A2 is 
responsible for about 13% of the cytochrome P450 activity 
of the liver and is involved in the metabolism of several 
commonly used drugs (e.g., caffeine, clozapine, flutamide, 
lidocaine, melatonin, mexiletine, etc) and endogenous 
compounds [35]. Expression of CYP1A2 is primarily 
regulated by the aromatic hydrocarbon receptor (AhR) [35]. 
There is a great inter-individual CYP1A2 variability [36]. 
CYP1A2 activity also shows high inter-ethnic variability 
which can be attributed, in part, to differences in genetic 
variants and their frequencies [37] and possibly also to 
different lifestyle and environmental conditions across ethnic 
groups. CYP1A2 is an inducible enzyme whose activity is 
modified by various factors. On one hand, factors such as 
cigarette smoking, coffee consumption, intake of charcoal-
grilled meat, omeprazole and carbamazepine induce CYP1A2. 
On the other hand, fluvoxamine and oral contraceptives 
(OCs) inhibit CYP1A2 enzyme activity [35].  
 
Fig. (1). Top three pharmacogenomics applications at the nexus of renal pathophysiology and cardiovascular medicine, namely ACE 
inhibitor treatment, VDR antagonists and moderate dietary salt intake. Arrows represent the direct links as described in the scientific 
literature. The light blue band across PXR, CAR, VDR and AHR illustrates the tight interplay that exists among these genes. VIP = very 
important pharmacogenes; SS = genes that are involved in the blood pressure response to salt intake with various levels of evidence. 
Table 2. Selected VIP Pharmacogenomics Genes: Renal Function, Blood Pressure and Salt-sensitivity 
Level of Evidence Linking the Gene to: Gene Top Three Applications 
Renal Function Blood Pressure Salt-sensitivity 
ABCB1 Reduced salt intake + + + 
ACE ACE inhibitors, Reduced salt intake ++ ++ + 
CYP1A2  _ + _ 
CYP3A5 Reduced salt intake + + + 
MTHFR  + + _ 
PXR  _ (+) _ 
VDR VDR agonists + + _ 
 No evidence; (+) Indirect evidence; + Direct evidence; ++ Strong evidence. 
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 In addition to environmental factors, the inter-individual 
CYP1A2 variability could be due to genetic factors [38]. For 
example, the CYP1A2*1C allele, identified in the 5’-flanking 
region of the gene, could lead to direct decreased CYP1A2 
activity [39]. CYP1A2*1F allele has been suggested to 
confer a higher inducibility of CYP1A2 by smoking [40]. 
However, in a study with sequencing data on the entire 
CYP1A1/CYP1A2 locus, no single SNP or haplotype could 
unequivocally predict CYP1A2 activity [24], and none of  
the currently identified CYP1A2 polymorphisms seems to 
explain the large inter-individual variability in CYP1A2 
activity.  
CYP1A2 and Kidney Function 
 There are data suggesting a relationship between the 
CYP1A2 gene, CYP1A2 enzymatic activity and kidney 
function. These data come notably from studies showing 
that, in CKD patients, metabolic clearance of drugs, and 
particularly drugs metabolized by cytochrome P450, are 
decreased [41]. Decreased clearance could be due to a 
decrease in P450 protein expression, which in turn, would be 
secondary to a reduced gene expression. To better determine 
which CYP-P450 gene and isoform were down-regulated in 
CKD, renal failure was induced in animal model and the 
effects on protein expression, gene expression, and P450 
isoform activity investigated [42]. Compared to control 
animals, CKD mice had a reduced level of CYP1A2 protein 
expression (- 56%, p<0.05). In addition, a significant 
decrease in mRNA levels of CYP1A2 protein was also 
observed in CKD mice, which could explain the decrease in 
protein expression. While this study and others [41] confirm 
that the decreased clearance is secondary to a decrease in 
P450 gene and protein expression, association of CYP1A2 
with kidney function itself has not been shown. CYP1A2 was 
not among the loci uncovered in association with GFR, 
CKD, or albuminuria in GWAS studies [43-46]. At the time 
being, it seems that CYP1A2 gene does not have a major 
direct influence on kidney function. 
CYP1A2 and Blood Pressure 
 Contrary to kidney function, evidence on an independent 
association of CYP1A2 with blood pressure is available. 
GWAS have identified the region nearby CYP1A2 as being 
robustly associated with blood pressure and hypertension 
[47]. Compared to A allele, the rs1378942 C variant was 
associated with higher diastolic blood pressure (beta 
coefficient: 0.41 mm Hg per copy of the C allele, standard 
error [SE]: 0.06, p value 2 x 10
-12
) and with a 10% increased 
risk of hypertension (Odds ratio [OR], 1.10, 95%CI 1.07-
1.12, P value=2 x 10
-14
) [47]. A joint meta-analysis of the 
CHARGE and Global BPGen studies identified a region 
adjacent to CKS-ULK3-CYP1A2 (rs6495122) as a genome-
wide significant loci for diastolic blood pressure (beta 
coefficient: 0.40, SE: 0.06, p value=1.8 x 10
-10
) [48]. This 
signal was also identified in GWAS conducted in African-
American (rs6495122, p value=3.7 x 10
-4
) [49] and Japanese 
(rs1378942, p=6 x 10
-3
) [50] populations, but not in two 
other GWAS conducted in east Asians [51] and Han Chinese 
population [52]. This suggests that the CKS-ULK3-CYP1A2 
locus does confer some susceptibility to hypertension, but 
probably not across all race/ethnicities.  
 CYP1A2 polymorphisms have been previously associated 
with disease susceptibility such as cancers, porphyria 
cutanea tarda, spontaneous abortion [53], but never with 
hypertension until these recent GWAS. The mechanisms by 
which CYP1A2 influences blood pressure remain to be 
determined. Given the large (>100) number of substrates -
including drugs (e.g. clozapine, caffeine), procarcinogens 
(e.g. aflatoxin b1), and endogenous substrates (e.g. steroids) 
reported for CYP1A2, the mechanisms could largely be 
mediated by CYP1A2 substrates.  
 Although limited compared to other CYP-family genes, 
data on CYP1A2 pharmacogenomics are available and the 
topic has been reviewed elsewhere [54]. The main attention 
has been paid to antipsychotic drugs, theophylline, and 
melatonin [38]. With respect to antihypertensive drugs, the 
focus has been made on CYP2C9, which metabolizes several 
antihypertensive angiotensin II receptor antagonists, such as 
losartan, irbesartan, candesartan and valsartan. For example, 
the CYP2C9 genotype has been shown to influence losartan 
metabolism and to predict the blood pressure response to 
irbesartan [55]. Concerning CYP1A2, the results from a 
nutrigenomic study provide additional mechanistic hypo- 
theses on the relationship between CYP1A2 and blood 
pressure. In a matched case-control study (N=4,028) of 
subjects living in Costa Rica, an increased risk of myocardial 
infarction with increasing coffee consumption has been 
reported among carriers of the CYP1A2 C variant [56]. For 
carriers of the slow metabolizing *1F allele, the adjusted OR 
(95%CI) of nonfatal myocardial infarction associated with 
consuming < 1, 1, 2-3, and 4 or more cups of coffee per day 
were 1.00 (reference), 0.99 (0.69-1.44), 1.36 (1.01-1.83), and 
1.64 (1.14-2.34), respectively. Corresponding ORs for 
individuals with the rapid *1A/*1A genotype were 1.00, 0.75 
(0.51-1.12), 0.78 (0.56-1.09), and 0.99 (0.66-1.48) (P value 
for gene x coffee interaction=0.04). The increased risk has 
been attributed to a prolonged presence of caffeine in the 
circulation among slow metabolizers due to lower enzyme 
activity. Through a comprehensive search of the human 
genome involving over 40,000 participants, Cornelis et al. 
recently discovered AHR and CYP1A1/CYP1A2 locus 
associated with habitual caffeine consumption [57]. Caffeine 
is the most widely consumed stimulant in the world, with an 
estimated 80-90% of adults reporting regular consumption of 
caffeine-containing beverages [58]. The effects of coffee or 
caffeine intake on health in general and on cardiovascular 
disease, in particular, have been assessed with inconclusive 
results [59]. On the short term (i.e. less than 3 months), 
regular coffee or caffeine intake increases blood pressure 
[60], but a tolerance to the acute cardiovascular effects of 
caffeine has been described. There is no clear evidence that 
regular caffeine intake on the long run increases the 
incidence of hypertension [61, 62]. It is therefore not clear 
whether a phenomenon similar to the increased risk of 
myocardial infarction associated with increasing coffee 
consumption among carriers of specific CYP1A2 variant 
could explain, at least in part, the increase risk of hyper- 
tension associated with CYP1A2 variants in some GWAS 
studies. Finally, as the CKS-ULK3-CYP1A2 locus contains 
many other genes than CYP1A2, further work is needed to 
know which gene is causally associated with blood pressure 
and hypertension. 
Renal Function and Pharmacogenomics Current Pharmacogenomics and Personalized Medicine, 2011, Vol. 9, No. 4    303 
 In summary, CYP1A2 encodes the CYP1A2 enzyme, 
which has a large number of endogenous and exogenous 
substrates. There is a great inter-individual CYP1A2 
variability, which seems to be mainly due to environmental 
factors, but signals near the CYP1A2 gene have been 
identified and replicated in at least three GWAS. The 
putative mechanism of association between CYP1A2 and 
blood pressure is currently unknown. Possible mechanisms 
include an action mediated by CYP1A2 substrates, notably 
caffeine, and genes located near the signal. 
2.1.2. CYP3A5 Gene  
 Members of the human cytochrome P450 (CYP) 3A 
subfamily (mainly CYP3A4 and CYP3A5) play an important 
role in drug metabolism [63]. It is currently considered that 
CYP3A activity accounts for about 50% of hepatic CYP 
activity, attributable mainly to the CYP3A4 enzyme [64, 65]. 
Yet, CYP3A4 and CYP3A5 have very similar substrate 
specificities [65]. The CYP3A5 gene is located on 
chromosome 7q22.1, in a gene cluster containing also 
CYP3A4, CYP3A43 and CYP3A7. The existing linkage 
disequilibrium between the CYP3A4 and CYP3A5 loci may 
make it difficult to clearly identify which is the true 
underlying causal variant. In this review, we concentrate on 
the CYP3A5 gene because of its association with blood 
pressure and renal function [28, 30, 66] and because it is the 
predominant CYP3A form in the kidney [67]. The CYP3A5 
gene displays high nucleotide diversity in Caucasians [68] 
and appears to be under high selective pressure in non-
Africans [69]. CYP3A5 is expressed in the kidney, liver, 
intestinal tract, adrenal gland and lung [64, 67, 70].  
 Unlike what is observed for CYP3A4, there is a strong 
association between CYP3A5 genetic variants and CYP3A5 
activity. The CYP3A5 rs776746 variant (6986G>A), located 
in intron 3, which determines the CYP3A5*3 (6986A) allele, 
influences mRNA splicing and leads to a premature stop 
codon as well as greatly reduced CYP3A5 enzymatic activity 
[25]. The wild type CYP3A5*1 allele (6986G) is associated 
with high CYP3A5 activity and only people carrying the 
CYP3A5*1 allele express large amounts of CYP3A5 [25]. 
Alleles other, and less frequent, than CYP3A5*3 are 
associated with reduced CYP3A5 activity, such as the 
CYP3A5*6 (which lead to a splicing defect) and CYP3A5*7 
(which leads to a frameshift with premature termination of 
translation) alleles [64]. The frequency of the CYP3A5*3 
allele, which varies substantially across ethnic groups and 
geographical locations, is significantly correlated with 
distance from the equator [69]. The frequency of the 
CYP3A5*1 allele ranges from 36% to 94% in people of 
African descent, from 5% to 15% in Caucasians and from 
23% to 40% in Asians [64, 69, 71-73]. The regulation of 
CYP3A5 expression seems to be influenced by multiple 
nuclear receptors, such as the glucocorticoid receptor (GR) 
[74, 75], pregnane X receptor (PXR) [76] and constitutive 
androstane receptor-beta (CAR) [76]. Smoking was found to 
reduce CYP3A5 expression in vitro [74]. 
CYP3A5, Blood Pressure and Hypertension 
 Many candidate gene studies have explored the 
association between CYP3A5 variants and blood pressure or 
hypertension in humans [29]. So far, results have been 
inconsistent. Furthermore, the CYP3A5 locus did not come 
out in GWAS for blood pressure and hypertension [47, 48, 
51, 77]. The CYP3A5*1 allele was associated with higher 
blood pressure in some studies [67, 72, 78, 79], with lower 
blood pressure in other studies [80, 81] or was not associated 
with blood pressure in other studies [72, 79, 81, 82]. In  
a meta-analysis including 2799 cases and 6794 controls  
from ten studies, Xi et al. found the CYP3A5 rs776746 
polymorphism to be significantly associated with blood 
pressure in Caucasians only [66]. Caucasian carriers of the 
CYP3A5*1 allele had lower systolic blood pressure (-1.3 mm 
Hg, 95% confidence interval:-2.401;-0.242) than non-
carriers. In a case-control study including 250 pregnant 
women with and 250 without hypertension, CYP3A5 
rs776746 was not associated with hypertension in pregnancy 
[83]. In a large population-based study (Rotterdam study) 
[84], a genetic risk score composed of three “salt-sensitivity” 
variants (CYP3A5 rs776746; ADD1 G460T and GNB3 
rs2301339) was associated with blood pressure in type 2 
diabetic patients only. 
 There are several mechanisms by which CYP3A5 may 
influence blood pressure, if it does. CYP3A5 converts 
cortisol to 6 beta-hydroxycortisol in the kidney [85, 86]. In 
rats, CYP3A activity correlates with systolic blood pressure 
[86] and inhibitors of CYP3A activity decrease the level of 6 
beta-hydroxycortisol and blood pressure [85]. In humans, 
some evidence suggest that CYP3A5*1 carriers may have 
increased proximal tubular sodium reabsortion [28, 67, 72]. 
Hence, CYP3A5 could influence blood pressure by sodium 
and water retention in the kidney. The CYP3A5 gene may 
therefore represent a salt-sensitivity gene, as detailed below. 
Fromm et al. [80] found people carrying the CYP3A5*3/*3 
genotype to have lower serum aldosterone values. Eap at al 
[30] found that the CYP3A5*1 allele tended to be associated 
with higher plasma aldosterone levels. It therefore appears 
that CYP3A5 variants may be associated with activity of  
the renin-angiotensin-aldosterone system, which is a key 
regulator of blood pressure.  
CYP3A5 Pharmacogenomics  
 As already mentioned, CYP3A4 and CYP3A5 have 
similar substrate specificity [65]. Among CYP3A substrates, 
we can mention the following drugs prescribed in cardio- 
vascular conditions: amlodipine, atorvastatine, celiprolol, 
cerivastatin, digoxin, diltiazem, enalapril, felodipine, losartan, 
lovastatin, nicardipine. Nifedipine, pravastatin and verapamil 
[65, 87]. So far the majority of pharmacogenetic studies on 
CYP3A5 concentrated on tacrolimus, midazolam and 
ciclosporin [64]. CYP3A5 genotypes clearly influence the 
pharmacokinetics of the immunosuppressant tacrolimus in 
vivo [64]. A limited number of studies have analyzed the role 
of CYP3A5 variants on the response to CYP3A substrates 
used to treat cardiovascular conditions and most of these 
studies were small-sized, which increases the risk of false 
positive results and limits their external validity. CYP3A5 
variants appear to influence the pharmacokinetics of statins 
[88]. Carriers of CYP3A5*1 may have diminished pharma- 
cological effect of verapamil [89], a nondihydropyridine 
calcium channel blocker that can be used to treat 
hypertension. Eap et al. [30] found the combined action of 
CYP3A5 and ABCB1 variants to be associated with altered 
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response to lisinopril, an ACE inhibitor. In the randomized 
African-American Study of Kidney Disease and Hyper- 
tension Trial, CYP3A5 rs776746, unlike CYP3A4 variants, 
was not associated with blood pressure response to amlodipine 
[90]. In 40 healthy Korean men [91], carriers of the 
CYP3A5*3/*3 genotype had lower plasma concentration of 
amlodipine than CYP3A5*1 carriers but the blood pressure 
response to amlodipine was similar. 
CYP3A5, Salt-sensitivity and Dietary Salt Intake 
 Ho et al. [72] found CYP3A5*1 carriers to be more salt-
sensitive than non-carriers. The frequency of the CYP3A5*3 
allele is significantly correlated with distance from the 
equator and has similar geographic distribution than the AGT 
M235T, a variant associated with blood pressure and 
hypertension [69]. According to Thompson et al. [69], these 
results suggest that genetic variants influencing blood 
pressure sensitivity to salt underwent selective pressure that 
shaped their geographical distribution. In 375 people of 
African descent, CYP3A5*1 carriers tended to have higher 
age-related increase in blood pressure and proximal tubular 
sodium reabsorption than non-carriers [28], which suggests 
that the CYP3A5*1 allele is associated with high blood 
pressure sensitivity to salt. In the same group of people, 
whenever urinary sodium excretion was high, the CYP3A5*1 
allele was associated with higher blood pressure in the 
absence of the ABCB1 3435T allele [30]. In this latter  
study [30], there was a significant gene-gene-environment 
(CYP3A5-ABCB1-salt intake) interaction. Similarly, in 238 
Japanese men [92], the association of the CYP3A5 rs776746 
with blood pressure differed by salt intake level (i.e., gene-
by-environment interaction). In 6777 participants to the 
PREVEND study [81], systolic blood pressure and pulse 
pressure were significantly lower in carriers of CYP3A5*1 
with effect modification by sodium intake. In this latter 
study, men carrying the CYP3A5*1 allele had lower urinary 
sodium excretion than non-carriers and a similar, although 
not significant, trend was observed in women [81]. 
 Plasma peak concentration following oral administration 
of quinidine, a CYP3A substrate, was found to be lower 
under high dietary salt intake than under low salt intake [93]. 
Similarly, high dietary salt intake was associated with lower 
plasma peak concentration of orally administered verapamil 
[94]. No such effects were observed after i.v. administration 
[93, 94]. These data suggest that dietary salt intake may 
influence the intestinal disposition of drugs metabolized by 
CYP3A. In rats, high-salt diet increased Cyp3a3 expression 
and protein levels in the liver and intestine, but not in the 
kidney [95], which suggests that the effect of salt intake on 
gene expression and enzymatic activity is tissue-specific. 
Surprisingly little has been published during the past 10 
years about the role (or the absence of role) of dietary salt 
intake on drug disposition. Kosuge et al. [96] recently 
observed in vitro that the transcription of CYP3A5 is 
influenced by the osmotic environment in various cell lines, 
a process driven by Nuclear factor of activated T cells 5 
(NFAT5), also called tonicity-responsive enhancer binding 
protein. Considering the key role of salt in driving osmotic 
forces, it is conceivable that high dietary salt intake may 
influence intestinal drug disposition. More generally, tonicity 
changes within the intestinal lumen following the intake of 
selected food items may well influence CYP3A expression 
[96] and therefore intestinal disposition of drugs and 
endogenous compounds that are CYP3A substrates.  
CYP3A5 and Renal Function 
 There is little data regarding the association between 
CYP3A5 variant and renal function. Givens et al. [67] found 
higher creatinine clearance CYP3A5*1 carriers in a study 
including 25 African Americans. Bochud et al. [28] found 
that CYP3A5*1 carriers had lower GFR estimated using 
inulin clearance than non-carriers in a study including 375 
people of African descent. Lieb et al. [82] found no 
association of CYP3A5*1 with estimated GFR in women, but 
a weak association with lower estimated GFR in men. 
Fromm et al. [80] found no association of CYP3A5*1 with 
GFR in 115 young Caucasian men. Further studies are 
clearly needed to clarify the role of CYP3A5 variants in renal 
function in humans. 
 In summary, there is strong correlation between CYP3A5 
variants and CYP3A5 activity. Yet, there are large inter-
individual and inter-ethnic variations in CYP3A5*1 allele 
frequency. There is some evidence that the CYP3A5 gene is 
associated with blood pressure control and some indirect 
evidence that it may influence salt-sensitivity in humans. 
Further studies are needed to confirm and further explore 
these relationships. Similarly, the association of CYP3A5 
variants with renal function reported in a few studies needs 
further confirmation. Among the putative mechanisms for 
the association with blood pressure is the convertion, by 
CYP3A5, of cortisol into 6 beta-hydroxycortisol in the 
kidney. It would be of major interest to also clarify  
the putative role of CYP3A5 activity on intestinal drug 
disposition following various dietary salt intake levels.  
2.2. Transporters 
2.2.1. ABCB1 Gene 
 The ABCB1 gene encodes the P-glycoprotein (Pgp), 
which belongs to the superfamily of human ABC 
transporters. The gene contains 29 exons and is located on 
chromosome 7q21.12. ABCB1 is also known as the multi- 
drug resistance (MDR) gene because its overexpression in 
cancer cells leads to resistance to various anticancer drugs. 
Several ABCB1 genetic variants have been shown to 
influence Pgp expression in humans, including the 3435 C>T 
and 2677 G>T variants. The 3435 C>T variant, although 
non-synonymous, influences mRNA stability [97] as well as 
Pgp substrate stability [98]. Pgp is expressed in many 
organs, including kidney, adrenal gland, liver, brain, testis 
and intestine. In the kidney, Pgp has been found in endo- 
thelial cells [99], on the apical surface of proximal tubular 
epithelial cells [100], in the mesangium, in Henle’s loop and 
collecting duct [101]. The regulation of Pgp expression 
seems to be influenced by multiple nuclear receptors, such as 
pregnane X receptor (PXR) [102], constitutive androstane 
receptor-beta (CAR) [103] and vitamin D receptor (VDR) 
[104-106]. 
 Pgp is a very efficient efflux pump that transports many 
endogenous substrates (e.g. steroids, lipids, phospholipids 
and cytokines), drugs (e.g. digoxin, cyclosporine, tacrolimus, 
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diltiazem, verapamil, etc), and other exogenous substrates 
out of the cells [107]. Among Pgp substrates, we will 
highlight the links with endogenous hormones that influence 
blood pressure, i.e. aldosterone and cortisol [108]. For a list 
of drugs that are substrates or modulators of Pgp, see the 
extensive review by Zhou [109]  
ABCB1, Blood Pressure and Salt-sensitivity 
 Increasing evidence points toward a role of Pgp in the 
regulation of the renin-angiotensin-aldosterone system [108, 
110-120], which is an important regulator of blood pressure 
and sodium handling by the kidney. Some reports suggest 
that Pgp is directly linked to endogenous components of  
the renin-angiotensin-aldosterone system. Pgp is probably 
involved in the transport of aldosterone in rodents and  
in humans [108, 110, 111]. In young healthy women, the 
ABCB1 3435C>T variant was associated with serum 
aldosterone level during the normal menstrual cycle [112]. 
The ABCB1 3435C>T was associated with the aldosterone 
and urinary sodium excretion responses to angiotensin II 
stimulation in young health men [118]. The ABCB1 
3435C>T was associated with circulating endogenous 
ouabain levels, a hormone produced in the adrenal gland 
known to regulate, together with aldosterone, the activity of 
the sodium pump, a key player in blood pressure control 
[120].  
 Several reports point toward biological interactions 
between Pgp and drugs influencing the renin-angiotensin-
aldosterone system. Losartan, an angiotensin-receptor 
blocker, is a Pgp substrate. Pgp appears to inhibit the efflux 
of aliskiren, a renin inhibitor used in the treatment of 
hypertension, in the small intestine [119]. Spironolactone, a 
non-specific aldosterone antagonist, up-regulates Pgp 
expression and efflux activity in vitro [113]. Telmisartan and 
the prodrug candesartan-cilexetil, angiotensin receptor type 1 
blockers, were found to significantly inhibit Pgp activity 
[121, 122], which implies that important drug-drug inter- 
actions may occur when these drugs are combined with Pgp 
substrates. Studies in rats [123] and humans [124] found  
that the Pgp inhibitor cyclosporine A influences the renin-
angiotensin-aldosterone system. Cyclosporine A belongs to 
the group of calcineurin inhibitors used to induce immuno- 
suppression after organ transplantation. Presence of the 
ABCB1 variant haplotype 1236T/2677T/3435T in the donor 
was associated with long-term decrease in renal function in 
kidney transplant recipients receiving cyclosporin A [125]. 
By contrast, ABCB1 variants were not associated with renal 
function in 160 heart transplant recipients on calcineurin 
inhibitor treatment [126]. Finally, there is ample evidence 
suggesting that Pgp is involved in cyclosporine-induced 
post-transplantation nephrotoxicity [127-129], likely by 
influencing cyclosporine absorption [130]. Cyclosporine-
induced post-transplantation nephrotoxicity is frequently 
associated with arterial hypertension. 
 Pgp plays a role in the transport of cortisol at the blood–
brain barrier [131, 132]. Pgp may therefore influence local 
glucocorticoid activity in selected regions of the brain. 
Excess of glucocorticoids, whether of exogenous (e.g. 
glucocorticoid treatment) or endogenous (e.g. Cushing’s 
syndrome) origin, often leads to arterial hypertension, but  
the pathophysiological mechanisms are so far not well 
understood [133]. An excess of glucocorticoids may increase 
blood pressure via several mechanisms: (1) activation of the 
mineralocorticoid receptor and resulting enhanced renal 
sodium reabsorption, (2) activation of the renin-angiotensin-
aldosterone system, (3) induction of sleep apnea and insulin 
resistance, (4) decreased vasodilation and (5) increased 
vasoconstriction [134]. 
 Pgp not only has many substrates, but also many 
inhibitors and inducers [107, 135]. Numerous exogenous 
substances, including drugs, were found to inhibit (e.g. 
curcumin, ginsenosides, bergamottin from grapefruit juice, 
cyclosporin) or activate (e.g. clotrimoxazole, St John’s wort, 
some catechins from green tea) Pgp activity [107, 135] . 
Grapefruit juice was found to activate the transport of drugs 
by Pgp in vitro [136]. In rats, high salt diet substantially 
decreased mdr1a and mdr1b expressions and Mdr1 protein 
levels (these are the rat equivalents of ABCB1 and Pgp in 
humans) in the kidney and liver, while an increase occurred 
in the intestine [95, 137]. This further emphasizes the 
potential for gene-environment, drug-environment and drug-
drug interactions to modulate the effects of Pgp on blood 
pressure and renal function. 
ABCB1 and Renal Function 
 Although humans express a single Pgp gene (ABCB1 or 
MDR1), rodents share the function of mdr1 between two 
highly homologous genes, mdr1a and mdr1b. Single 
knockout (KO) mdrd1a (-/-) mice are viable and fertile, but 
they display increased neurotoxicity to ivermectin and 
vinblastine [138], but their renal function has not been 
determined [139]. Double Pgp KO mice [mdrd1a/mdr1b (-/-)] 
have higher mean arterial pressure, proteinuria and 24-hour 
urine volume, reduced GFR and renal plasma flow compared 
to wild-type mice [139]. Furthermore these KO mice have 
higher lithium clearance, which suggests reduced proximal 
tubular sodium reabsorption, and show evidence of proximal 
tubular dysfunction [139]. By contrast KO mice were 
protected against ischemic renal injury [139]. Under normal 
conditions, mdrd1a/mdr1b (-/-) mice have higher water 
intake than wild-type mice and under low salt diet, KO mice 
display a rise in plasma aldosterone levels, unlike wild-type 
mice [139]. Mdrd1a/1b (-/-) mice have higher aldosterone 
activity in the plasma, brain and heart than wild-type mice, 
which suggests that Pgp is crucial in aldosterone disposition 
[114]. These animal data strongly suggest that Pgp plays a 
key role in blood pressure and renal function, in particular 
proximal tubular function. 
 In 290 people of African descent, the 2677T and 3435T 
ABCB1 alleles were associated with higher GFR, measured 
using inulin clearance and higher effective renal plasma 
flow, measured using PAH clearance [31]. In the same study, 
we found ABCB1 variants to be significantly associated  
with estimated GFR in a large population-based study in 
Caucasians [31]. These observational epidemiological data 
in humans suggest that the ABCB1 gene is indeed a 
candidate gene for renal function in humans. Yet, this gene 
has not been identified in large scale genome-wide associa- 
tion studies (GWAS) on renal function [43, 140, 141], CKD 
[43, 140, 141] or microalbuminuria [44]. One possibility to 
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explain this lack of replication is that these GWAS meta-
analyses were underpowered to detect all relevant genetic 
variants with small effect sizes, another one is that gene-
environment interactions may obscure the role of this gene 
when pooling results across studies and, finally, these [31] 
may have been false positive results. Furthermore, we found 
the 3435T ABCB1 and CYP3A5*1 variants to interact with 
dietary salt intake for their effect on ambulatory blood 
pressure [30]. Hence the association of the 3435T ABCB1 
variant with blood pressure could only be observed when 
taking CYP3A5*1 status and dietary salt intake into account. 
This may explain why the ABCB1 gene has not been 
identified in GWAS meta-analyses for blood pressure and 
hypertension [47, 48, 77]. Here again, in the absence of 
replication, false positive results [30] cannot be excluded. 
 Cadmium, a common environmental pollutant, enhances 
the expression of ABCB1 in vitro [142, 143]. Renal proximal 
tubular cells that overexpress Pgp are more resistant to the 
toxic effects of cadmium [144]. In humans, chronic exposure 
to cadmium leads to its accumulation in the kidney with 
subsequent kidney damage, in particular in the proximal 
tubules [45]. Another possible link between kidney damage 
and chronic exposure to cadmium is via blood vessel damage 
in the kidney. All layers of the wall of blood vessels (intima-
media-adventitia) are a target for cadmium deposition [145]. 
Chronic exposure to cadmium has been associated with 
atherosclerosis in humans and in animals [146]. In the 
population-based NHANES study, high blood cadmium 
levels were associated with increased risk of albuminuria and 
reduced GFR [147]. However, according to Nawrot et al., 
cadmium-induced kidney damage may not drive cadmium-
related mortality [45]. By contrast, there is no clear 
association between 24-h urinary cadmium excretion, a 
marker of lifetime exposure to cadmium, and blood pressure 
or hypertension [45]. Further studies are needed to clarify the 
role of Pgp in cadmium-induced nephropathy. 
 In summary, variants within the ABCB1 gene and its 
product, Pgp, may influence blood pressure and renal 
function in many different ways, not only via action on, and 
interaction with, endogenous substances (including 
components of the renin-angiotensin-system), but also via 
their effects on the transport of many drugs and other 
exogenous substrates or effect modifiers (including environ- 
mental pollutants and dietary factors). Disentangling the 
specific effects of Pgp substrates and effect modifiers, as 
well as their possible interactions, in complex living 
organisms such as mammals is a daunting task and much 
remains to be done to better understand how Pgp may 
regulate blood pressure and renal function. There is a clear 
lack of experimental studies in humans aiming at under- 
standing the role of Pgp under physiological conditions  
as well as in response to selected stressors such as low and 
high salt intake. Also, we do not know if, and to what extent, 
Pgp may play a role in the progression toward CKD in 
humans.  
2.3. Nuclear Receptors 
2.3.1. VDR Gene 
 The VDR gene is located on chromosome 12q13.1 and 
encodes the vitamin D receptor (VDR) [148]. VDR is 
expressed in most cells of mammals, but primarily in 
intestine, bone and kidney. VDR is widely expressed in the 
human kidney, namely in epithelial cells of the proximal and 
distal tubules, collecting duct and glomerulus [149]. VDR  
is a ligand-induced nuclear receptor that regulates the 
expression of over 900 genes throughout the genome [150, 
151], among which ABCB1 [104-106], CYP24A1 [150], 
CYP3A4 [152], CYP3A7 [150], FGF23 [153], SLC34A3 
[153] and TRPV6 [150, 154]. VDR is a protein that plays  
a crucial role in the biological responses to vitamin D,  
the synthesis of which is briefly presented below. However, 
VDR may also have vitamin-D independent actions triggered 
by low-affinity ligands such as lithocholic acid [152], 
curcumin and polyunsaturated fatty acids [155]. 
 Vitamin D is derived from three sources: 1) sunlight –the 
main source–, 2) diet, and 3) dietary supplements [156]. The 
solar ultraviolet V (UVB) causes photolysis of the 7-
dehydrocholesterol (provitamin 3) to previtamin D3 and then 
to vitamin D3 (cholecalciferol) in the plasma membrane of 
skin cells (PMID 12520530). Diet and dietary supplements 
are sources of vitamin D3 and vitamin D2 (ergocalciferol). 
Both vitamin D3 and D2 enter the blood circulation and  
are attracted to the vitamin D binding protein (VDbp). A  
first hydroxylation by CYP27A1 in the liver produces  
the 25-hydroxyvitamin D [25(OH)D], while a second 
hydroxylation (i.e., 1 alpha hydroxylation) by CYP27B1 in the 
kidney produces the 1,25-dihydroxyvitamin D [1,25 
(OH)2D3], which is the hormonally active form [157]. 
Extrarenal 1,25(OH)2D3 can also be produced and 1,25 
(OH)2D3 can act locally in the tissues where it is produced 
[158]. 
 While some of 1,25(OH)2D3 actions take place directly 
in the cellular membranes without interaction with the 
cellular nucleus (i.e. vitamin D rapid response), 1,25(OH) 
2D3 mostly acts through binding specific intracellular 
receptors (i.e. vitamin D genomic responses) [159, 160]. The 
1,25(OH)2D3 dissociates from the VDbp, enters the cell  
and interacts with the vitamin D receptor and activates it. 
The VDR-1,25(OH)2D3 complex translocates from the 
cytosol to the nucleus where it is joined by the Retinoid X 
Receptor (RXR), to form the vitamin D response elements 
(VDRE). The complex then binds to specific sequence in  
the promotor of reponsive genes and modulates the gene 
expression [160].  
 In the intestine, the VDR-1,25(OH)2D3 complex 
regulates genes that are involved in the absorption of 
calcium and phosphate, while the VDR-1,25(OH)2D3 
complex regulates the parathyroid hormone synthesis in the 
parathyroid glands. But the VDR protein is widely 
distributed in humans (e.g., lung, colon, kidney) and VDR 
abundance and activity seems to play an important role in the 
individual responsiveness to 1,25(OH)2D3. Some of the 
VDR abundance and activity is determined by VDR poly- 
morphisms [161]. 
 The coding sequence of the VDR gene includes eight 
exons. Several polymorphisms have been identified but four 
of them are common and have often been studied (FokI, 
BsmI, TaqI, ApaI). FokI is located at the VDR start codon 
and affects the length of the VDR protein resulting in a 
change in VDR activity [161]. BsmI, TaqI, and ApaI 
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polymorphisms are located in the UTR region of the VDR 
gene and are unlikely to change the VDR structure. How- 
ever, these polymorphisms might alter transcriptional activity 
and mRNA degradation, and thus VDR abundance, which  
is an important mechanism for the modulation of cellular 
responsiveness to 1,25(OH)2D3. 
Vitamin D, VDR, and Kidney Function 
 The kidney 1 alpha hydroxylation is decreased in kidney 
failure, and patients with ESRD typically suffered from 
1,25(OH)2D3 vitamin D deficiency, while usually keeping a 
normal 25(OH)D level [162]. Vitamin D therapy is often 
prescribed to ESRD patients with secondary 1,25(OH)2D3 
deficiency. The causal role of vitamin D deficiency on 
kidney failure has only been explored recently. In 2009, 
Ravani et al. showed that baseline low 25(OH)D levels were 
associated with an increase risk of ESRD [163] compared to 
patients with normal 25(OH)D levels . In a prospective 
cohort study of 9,000 hemodialysis patients, vitamin D 
therapy appeared to be associated with survival [164]. There 
are however no prospective, population–based studies of the 
association of 25(OH)D levels with change in kidney 
function or incidence of CKD other than ESRD. Experi- 
mental studies suggest that vitamin D levels can directly or 
indirectly prevent kidney failure. Kidney failure typically 
results from three kidney lesions: 1) tubulointerstitial 
fibrosis, 2) glomerulosclerosis, and 3) proteinuria [165]. The 
effects of paricalcitol (19-nor-1,25-hydoxy-vitamin D2), a 
synthetic vitamin D analogue, on tubulointerstitial lesions 
have been investigated in animal models. Compared with 
vehicle controls, paricalcitol significantly attenuated renal 
interstitial fibrosis [166] and both 1,25(OH)2D3 and 
oxacalcitriol (another vitamin D analogue) ameliorates 
glomerulosclerosis with reduction of type I and IV colla- 
genes in antibody-induced glomerulonephritis [167]. The 
reduction of albuminuria [168-170] or proteinuria [171] in 
CKD patients have been reported in three randomized 
controlled trials comparing placebo to vitamin D analogues. 
Oral calcitriol treatment reduced proteinuria in patients with 
IgA nephropathy [172]. Yet, another mechanism by which 
vitamin D can presumably modify kidney function is through 
the suppression of the renin-angiotensin system (RAS). The 
renal RAS plays a major role in determining the rate  
of chronic renal progression [173]. In 1986, Resnick et al. 
already reported that serum level of 1,25(OH)2D3 was 
inversely associated with the plasma renin activity in 
normotensive and hypertensive subjects [174]. Since then, 
1,25(OH)2D3 and paricalcitol were found to decrease 
angiotensinogen, renin, and renin receptor in animal models 
[175, 176]. This suggests that the beneficial effects of 
vitamin D analogues in chronic renal failure are due, in part, 
to down regulation of the RAS. 
 The role of VDR genetic variants on kidney function has 
been explored only recently and current data are mostly 
limited to ESRD. The influence of VDR polymorphism on 
ESRD was investigated 258 ESRD patients and 569 healthy 
controls [177]. A significant difference in the genotype 
frequencies of the ApaI, FokI and BsmI genotypes were 
found. In addition, the ApaI/TaqI/FokI/BsmI haplotype 
analysis revealed that subjects with a/t/F/b haplotype were  
at greater risk of ESRD (OR =11.0, 95%CI 1.38-87.7) [177]. 
This study confirmed the B allele to be the risk allele as 
being previously reported in a case-control study including 
222 subjects with and without ESRD [178]. 
 These results contrast with a previous report analyzing 
the influence of BsmI variants on PTH and 1,25(OH)2D3 in 
patient with different degrees of CKD before dialysis [179]. 
Most of the 248 patients included had moderate kidney 
failure (i.e., creatinine clearance 35-60 ml/min). In multi- 
variate analyses, calcitriol levels were less reduced in the BB 
genotype and the progression of hyperparathyroidism was 
slower in patients with Bsm1 BB genotypes than in the other 
types [179].  
 Albuminuria serves as an important predictive factor for 
the progression of kidney disease and for the development of 
cardiovascular disease. The contribution of genetic variants, 
including VDR, to the development of albuminuria has been 
evaluated in 5321 participants from the second phase (1991-
1994) of the Third National Health and Nutrition Examina- 
tion Survey (NHANES III), a population-based and 
nationally representative survey of the United States [180]. 
Albuminuria was evaluated as logarithm-transformed albumin-
to-creatinine ratio (ACR), as ACR  30 mg/g, and as ACR 
above sex-specific thresholds. IL1B (rs1143623) among 
Mexican Americans was significantly associated with 
increased sex-specific albuminuria. IL1B (rs1143623), CRP 
(rs1800947) and NOS3 (rs2070744) were significantly 
associated with ACR  30 mg/g among Mexican Americans 
(P < 0.05). In contrast, no variants were found to be associated 
with albuminuria among non-Hispanic blacks after adjust- 
ment for multiple testing. The only variant among non-
Hispanic whites significantly associated with any outcome 
was TNF rs1800750, which failed the test for Hardy-
Weinberg proportions in this population. Among Mexican 
Americans, haplotypes within ADRB2 (A-G), IL4r (C-A), 
and VDR (T-T) were associated with log(ACR) in crude 
genetic models only (P value <0.05). Age-sex adjusted 
models were only marginally associated with log(ACR). 
 Further information can be derived from the influence of 
VDR polymorphisms on CKD major risk factors; diabetes 
and hypertension (for hypertension, see below). BsmI VDR 
polymorphisms have been associated with diabetes and 
fasting glucose. Compared to men with BsmI Bb genotype 
(N=370) and bb genotype (N=245), carriers of BB genotype 
had higher levels of fasting glucose (5.61 vs 5.44 and 5.38 
mmol/l, p value <0.001) in individuals recruited during 
routine medical qualification for flying duty in Germany 
[181]. These associations were only reported in gene carriers 
with low physical activity [181]. The association of BsmI 
VDR polymorphism with type 2 diabetes mellitus was 
analyzed in 293 patients considered at high risk for coronary 
artery disease [182]. The prevalence of type 2 diabetes 
mellitus was gradually dependent on the number of B alleles 
(BB 28%, Bb 13%, bb 8%, P value = 0.002). The odds ratio 
of having type 2 diabetes mellitus was 3.6-fold higher among 
patients with the BB genotype compared with patients with 
the bb genotypes [182]. The relationship between VDR BsmI 
and FokI polymorphisms and anthropometric and bio- 
chemical parameters describing metabolic syndrome were 
tested in 176 randomly selected men in Poland. The BsmI 
VDR polymorphism seems to influence BMI and waist 
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circumference with BB carriers having higher BMI (29.0 vs 
26.8, p=0.024), and waist circumference (101.8 vs 92.3, p 
value=0.014) compared with bb genotypes. Fok1 VDR 
polymorphism appears to affect insulin sensitivity with FF 
and Ff carriers having higher level of fasting insulin then ff 
genotpyes (12.3 vs 9.8 vs 6.3, p value=0.008) [183]. In the 
rancho Bernardo study, a US community-based study of 
unrelated older adults without known diabetes, the genotypes 
frequencies of ApaI, BsmI, and TaqI polymorphism did not 
differ between persons with and without diabetes. Fasting 
plasma glucose and prevalence of glucose intolerance were 
higher in nondiabetic persons with aa genotype compared 
with those with AA genotype. BsmI bb genotype was 
associated with insulin resistance in subjects without 
diabetes [184]. In a brief genetic report, an association 
between ApaI genotype and insulin secretion was reported in 
a study of 164 healthy Bangladeshi Asians at risk for type 2 
diabetes; aa genotype was associated with a decrease insulin 
secretion compared to AA and Aa genotypes (68.5 vs 92.7 vs 
146.8, p value=0.001) [185]. In a separate publication but 
within the same study population, TaqI was associated with 
insulin secretion [186]. 
 The pharmacogenomics of vitamin D and kidney 
function have been largely unexplored so far. To the best of 
our knowledge, there is no study that explored the VDR 
genetic effect modification of the association between 
1,25(OH)2D3 and kidney function. Nor could we find study 
on the pharmacogenomics of vitamin D analogues with 
respect to kidney function. The lack of pharmacogenomics 
information on renal-related VDR pharmacogenomics is 
surprising given the association between vitamin D 
deficiency and CKD, and given the high prevalence of 
vitamin D supplementation / food fortification in North 
America [187]. There are inter-individual differences in 
vitamin D optimisation and recent evidence of lack of 
response to oral vitamin D in subjects who harbor specific 
VDR variants. In postmenopausal women, VDR BmsI and 
TaqI polymorphisms were association with non response to 
vitamin D oral supplementation [188]. Given the ongoing 
debate on recommendations of daily allowance of vitamin  
D, notably for cardiovascular disease prevention, further 
pharmacogenomics and nutrigenomics data should be 
gathered including in patient with non ESRD CKD who 
might benefit from vitamin D. 
Vitamin D, VDR, and Blood Pressure 
 Molecular, animal and human studies have established 
that vitamin D is associated with cardiovascular disease, 
including blood pressure. This topic has been reviewed 
elsewhere [189]. Three randomized controlled trials assessed 
the efficacy of vitamin D supplementation on blood pressure. 
Only one found a significant effect [190]. Compared with 
calcium alone (1,200 mg/day), vitamin D (800 IU/day) and 
calcium (1,200 mg/day) supplements resulted in 9.3% 
decreased systolic blood pressure (p = 0.02) in a 8-week trial 
including 148 women (mean age 74 years) with a 25(OH)D 
level < 50 nmol/l [190]. In 2008, Wang et al. [191] inves- 
tigated the associations of vitamin D intake with the 
incidence of hypertension in a 10-year prospective cohort of 
28,886 US women aged 45 or more years. Vitamin D intake 
was assessed from food frequency questionnaire. The risk of 
hypertension decreased in the higher quintiles of dietary 
vitamin D, even after adjustment for dietary calcium intake. 
This observation was reported for vitamin D intake from 
diet, not from supplements. Most of the large cross-sectional 
studies show a significant inverse association between 
25(OH)D levels and blood pressure [189]. The number of 
prospective studies examining 25(OH)D levels and the 
incidence of hypertension or change in blood pressure are 
limited and results are inconsistent. Most studies were small, 
had suboptimal blood pressure measurement (e.g., single 
measure of blood pressure), or did not control for potential 
confounders such as PTH.  
 Molecular evidence revealed actions of 1,25(OH) 2 D on 
mechanisms related to blood pressure. These mechanisms 
include a direct inhibition of 1,25(OH) 2 D on the RAS and 
nuclear factor-kappa B (NF-kB) pathway. VDR is expressed 
in the juxtaglomerular apparatus and modulates renin 
synthesis. Mice in which VDR was abolished are hyper- 
reninemic and present high blood pressure and cardiac 
hypertrophy [192]. By contrast, when VDR was over- 
expressed in the mouse juxtaglomerular apparatus, hypor- 
eninemia was noted [193]. NF-kB is a family of transcription 
factors that functions as a master regulator of immune 
response [194]. It regulates a wide range of genes involved 
in inflammation, proliferation and fibrogenesis and is known 
to have a key role in kidney disease [195]. Both the RAS  
and the NF-kB promote the production of profibrotic  
and pro-inflammatory factors, increase oxidative stress,  
and damage podocytes. In addition, vitamin D can regulate 
blood pressure through the prevention of secondary hyper- 
parathyroidism, effect on vascular cells and endothelial 
function. Vitamin D could potentially contribute to arterial 
stiffening and hypertension [196]. Another mechanism by 
which VDR may influence blood pressure is via its role  
in sex steroid metabolism [197]. Sex hormones have  
been found to influence systemic and renal hemodynamic 
response to salt [198]. In VDR null mice, the expression and 
activity of aromatase (CYP19A1), a key hormone in 
estrogen biosynthesis, was reduced in ovary and testis and 
circulating levels of LH and FSH increased compared to 
wild-type mice [199]. VDR null mice presented uterine 
hypoplasia that resulted from a lack of estrogen synthesis 
that was not observed in vitamin D-deficient mice [200]. In 
human cells, vitamin D increased the expression of 
CYP19A1 [201] and the convertion of 17-b-estradiol to 
estrone [202], which suggests that VDR mediates estrogen 
synthesis in humans as well. 
 Associations of VDR polymorphisms with blood pressure 
have been explored. In a study including 76 patients of 
Indian descent and 201 patients of African descent, vitamin 
D deficiency was significantly associated with increased 
diastolic blood pressure and triglyceride levels, and reduced 
high-density lipoprotein cholesterol (P<0.05) [203]. 
Prevalence of vitamin D deficiency was decreased in patients 
carrying the f allele of FokI (OR: 0.52, 95%CI 0.30–0.90, 
P=0.02) and the aa genotype of ApaI (OR: 0.46, 95%CI 
0.21–0.99, P=0.05). BsmI and TaqI SNPs were not 
associated with vitamin D deficiency [203]. 
 The prevalence of the VDR BsmI polymorphism and its 
association with anthropometric and biochemical features of 
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metabolic syndrome, including high blood pressure, were 
examined in 351 randomly selected healthy postmenopausal 
women. BsmI genotypes were not associated with blood 
pressure nor with other anthropometric or metabolic 
parameters except LDL cholesterol level, which was higher 
among BB carriers [204]. The relationship between VDR 
gene polymorphisms (Bsm-I, Apa-I and Fok-I) and target 
organ damage with essential hypertension was explored in 
74 patients without types 2 diabetes mellitus or impaired 
glucose tolerance and severe obesity [205]. No significant 
difference was detected in biochemistry results and physical 
examination between groups for Bsm-I and Apa-I VDR gene 
polymorphisms. A negative correlation was present between 
vitamin D levels and day-time interval and early morning 
average by the measurement of 24-hour ambulatory blood 
pressure in the non-FF group. In addition, the degree and 
presence of retinopathy were significantly higher in the non-
FF group when compared to the FF group (p = 0.025, p = 
0.018, respectively) [205]. An association of VDR poly- 
morphisms with 25-hydroxyvitamin D on blood pressure in 
apparently healthy subjects was also reported for BsmI 
[206]. In a cross-sectional study of 590 subjects and 
conducted in Spain, systolic blood pressure was higher  
in men with bb genotype than in the other genotypes  
(P < 0.006). This association was not seen among women 
[206]. 
VDR Gene and Salt-Sensitivity 
 No study has assessed the association between VDR 
genetic variants and salt-sensitivity. However, a recently 
published study found 25-hydroxyvitamin D to be associated 
with plasma renin activity and with salt-sensitivity in 
patients with low-renin hypertension in 223 Caucasian 
hypertensive patients [207]. 
 In summary, variants within the VDR gene and its 
product, VDR, may influence renal function and blood 
pressure. Randomized controlled trials provide convincing 
evidence that VDR agonists confer renoprotection in humans 
[168-170, 208]. Associations of vitamin D with renal 
function, and VDR gene with renal function, have been 
demonstrated, but there is a clear lack of data on the 
potential effect modification of VDR variants on the 
association between vitamin D and renal function. The 
existence of dietary (non-vitamin D) ligands of VDR 
suggests that gene-environment (i.e. VDR-diet) interactions 
may impact on the biologic actions of VDR, but this has  
not been studied so far. VDR variants have been associated 
with blood pressure (including 24-hour ambulatory blood 
pressure) and target organ damage. Evidence of associations 
between VDR variants and diabetes, a major CKD risk 
factor, and biochemical features of the metabolic syndrome 
have been reported. There is little data on VDR pharmaco- 
genomics, mostly limited to bone disease.  
2.3.2. PXR Gene  
 The Pregnane X Receptor (PXR) gene belongs to the 1I 
family of nuclear receptors, together with VDR and CAR. 
PXR is a ligand-regulated transcription factor that modulates 
the expression of many genes, including genes encoding for 
drug metabolizing enzymes and transporters [209]. PXR is 
located on chromosome 13q12-13.3 and includes 9 exons. 
Seven alternative transcripts have been described [210]. 
More than 200 PXR variants have been described so far, 
including several variants that alter the aminoacid sequence 
of PXR [211-217]. PXR is highly expressed in human liver, 
intestine, lung and kidney [218]. 
 PXR binds the enhancer elements located in the 
promoters of many genes, such as CYP2B9, CYP2C8, 
CYP2C9, CYP3A4, CYP3A7 and ABCB1, thereby influencing 
the expression of these genes [219]. Other gene targets of 
PXR are SULT2A, involved in bile acid detoxification [220], 
UGT1A1, OATP2, GSTA1, GSTA2 and MRP2, involved in 
bilirubin clearance pathway [221]. 
 Single nucleotide polymorphisms (SNPs) in the PXR 
gene could influence PXR activity as they have been shown 
to influence the expression of PXR gene targets [214], such 
as CYP3A4 [212, 216, 217, 222] and ABCB1 [217]. As the 
enzymes and transporters encoded by PXR target genes are 
involved in the control of many endogenous systems, PXR  
is expected to influence many normal physiological and 
disease processes even in the absence of drug treatment 
[209]. PXR is implicated in bile detoxification and cholestasis, 
bilirubin detoxification, adrenal steroidogenesis, lipid meta- 
bolism, bone homeostasis, retinoic acid metabolism and 
inflammation [209].  
 PXR activity is modulated by a vast array of agonists or 
ligands, such as drugs (e.g. digoxin, spironolactone, nife- 
dipine, rifampicine) and xenobiotics (e.g. polychlorinated 
biphenyls [PCBs], DDT, St John’s wort, sulforaphane) 
[211], but also endogenous compounds (pregnane, pro- 
gestrones, corticosterones, testosterone, lithocholic acids, 17-
a ethinylestradiol) [223, 224] and vitamins K2 and E [225, 
226]. In fact, PXR was named pregnane X receptor because 
of its ability to be activitated by C21 steroids [224]. Among 
PXR agonists are several endocrine-disrupting chemicals (e.g. 
17-a ethinylestradiol, DDT, PBCs, dioxins), i.e. compounds 
that may affect human reproductive function and fertility. 
Also, recent experimental studies in rats found dietary salt 
intake to modulate the expression of PXR differentially in 
the liver, kidney and intestine [95]. Unlike nuclear receptors 
such as estrogen receptors, PXR has high structural 
flexibility so that it can bind structurally very diverse ligands 
[211].  
 Increasing evidence suggests that there is an intensive 
crosstalk between nuclear receptors of the NR1I subfamily 
(i.e. PXR, VDR and CAR) [227]. These receptors share the 
ability to enhance the metabolism and elimination of toxic 
endogenous and exogenous substances [227]. Also, these 
receptors share multiple transcriptional targets (e.g. CYP2B6, 
CYP3A4, ABCB1, ABCB2, UGTA1, CYP24A1, SUL2A1) 
[220, 227, 228]. 
PXR, Blood Pressure and Salt-sensitivity 
 So far, no study has shown any evidence of a direct  
link between the PXR gene and blood pressure in humans. 
Yet, the role of PXR in adrenal steroidogenesis [209] is 
particularly relevant to blood pressure control. More 
generally, PXR is considered to influence glucocorticoid and 
mineralocorticoid homeostasis [197]. In mice, activation of 
PXR led to increased circulating levels of corticosterone and 
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aldosterone [229]. These mice had adrenal cortex hyper- 
trophy and lacked glucocorticoid circadian rhythm [229]. 
The action of PXR on the mineralocorticoid pathway makes 
it an ideal hypertension candidate gene. Also, there is some 
evidence the PXR may influence vascular tone during 
pregnancy in PXR knockout mice [230]. PXR-/- mice were 
resistant to the vascular relaxation due to 5b-dihydropro- 
gesterone treatment [230]. The authors of this latter study 
hypothesize that this PXR effect could be mediated via PXR-
activation of CYP epoxygenases [230]. The role of PXR in 
steroid hormone homeostasis has been shown to also act via 
induction, in the liver, of the phase II UGT1A enzyme, 
which is involves in the elimination of steroids, such as 
corticosterone, cortisol and cortisone, from the body [228]. 
Also, rifampicine, a PXR ligand, was found to lead to high 
urinary free cortisol excretion in humans [231]. However, 
the PXR locus did not come out in GWAS for blood pressure 
and hypertension [47, 48, 51, 77]. Also, we did not find any 
study providing a direct link between the PXR gene and 
blood pressure salt-sensitivity. 
PXR and Renal Function 
 We are not aware that any study ever found evidence for 
a direct link between the PXR gene and renal function in 
humans. The PXR locus was not uncovered as associated 
with CKD or other renal traits in GWAS [43, 44, 141]. Yet, 
recent evidence suggests that nuclear receptors in general, 
and PXR in particular, may play a role in renal diseases  
via their actions on lipid and energy metabolisms and 
inflammation [208].  
 In summary, although PXR is not currently considered as 
a gene involved in blood pressure or renal function, its role 
in controlling the expression of genes such as ABCB1 and 
CYP3A5, its involvement in steroid hormone metabolism, its 
actions on lipid and energy metabolism and inflammation as 
well as its interaction with VDR, all point toward PXR as 
being a putative important player in kidney diseases. The 
role of PXR as a xenobiotic and endobiotic sensor and its 
ability to bind to a large array of ligands, together with its 
numerous transcriptional gene targets, suggests that PXR 
may mediate complex gene-environment, drug-environment 
and drug-drug interactions with important consequences on 
human health, including kidney function. 
2.4. Other Pharmacogenes 
2.4.1. ACE Gene 
 The angiotensin converting enzyme (ACE) gene encodes 
ACE, an enzyme involved in the renin-angiotensin-
aldosterone system (RAAS) and in the kinin-kallikrien 
pathway that play a key role in blood pressure control. ACE 
is the target of ACE inhibitors, a family of drugs used to 
treat cardiovascular and renal diseases, including hyper- 
tension [232]. Renin converts angiotensinogen into 
angiotensin I, which is in turn converted by ACE into 
angiotensin II, the major effector of the RAAS. Among other 
functions, angiotensin II influences sympathetic tone, 
vasoconstriction and aldosterone secretion, which leads to 
sodium retention by the kidney.  
 The ACE gene is located on chromosome 17q23.3 and 
contains 26 exons. Alternative splicing leads two ACE 
isoforms. The most extensively studied ACE genetic variant 
is the 287-bp Alu-repeat sequence insertion/deletion poly- 
morphism located in intron 16 (ACE I/D) [233], with more 
than 4,000 publications during the past 20 years [234]. There 
is a high inter-individual variability in circulating ACE 
levels. The ACE I/D polymorphism explains about half of 
the phenotypic variance of circulating ACE levels [233], 
which highlights its functional importance. The D allele is 
associated with higher circulating ACE levels [233]. Yet, 
there is a controversy regarding the precise nature and 
location of the functional ACE polymorphism(s) [235]. Other 
ACE variants have been described and the genetic diversity 
of particularly high in people of African descent [235-237]. 
However, most studies have analyzed the ACE I/D poly- 
morphism and we will therefore concentrate on this variant. 
The ACE gene is expressed in many tissues including the 
kidney. 
ACE and Blood Pressure/Hypertension 
 Similarly to what is found for most blood pressure 
candidate genes in humans, results of associations between 
ACE variants and blood pressure and/or hypertension have 
been inconsistent, as illustrated by an absence of overall 
association in two meta-analyses [238, 239]. A major issue 
with the majority of candidate gene studies is their small 
sample size and hence low power to detect a small effect. By 
contrast, a meta-analysis including data on 11,000 Han 
Chinese found the ACE DD genotype to be associated with 
higher risk of hypertension when compared to the ACE II 
genotype (OR[95%CI] = 1.61 [1.32-1.96]), but there was a 
high degree of heterogeneity across studies [240]. The ACE 
locus did not come out in large genome-wide meta-analyses 
[47, 48, 51, 77]. In a recently published analysis of 30 gene 
regions encoding antihypertensive drug targets including 
data on 87,000 people, the ACE I/D (rs4305) variant  
was found to be modestly associated with hypertension 
[241]. Results regarding hypertension-related cardiovascular 
complications are also not consistent. In a meta-analysis 
including 6638 subjects from 28 studies [242], the ACE D 
allele was associated with higher left ventricular hypertrophy 
in never treated hypertensive patients, whereas no associa- 
tion was found in treated patients. The ACE I/D poly- 
morphism was not associated with the risk of myocardial 
infarction, ischemic heart disease or stroke in one meta-
analysis [239], whereas in another meta-analysis [238],  
the ACE D allele was associated higher risk of coronary 
heart disease, myocardial infarction, stroke and diabetic 
nephropathy. In a meta-analysis including 43,733 coronary 
artery disease cases and 82,606 controls [243], the ACE D 
allele was associated with higher risk of coronary artery 
disease (OR[95%CI]=1.25 [1.16-1.35]). In the latter study 
[243], there was a high degree of heterogeneity, in particular 
across ethnic groups. In this meta-analysis, the results were 
stronger in men [243]. Several studies have identified an 
effect modification of sex for the effect of the D allele on the 
risk of coronary artery disease [243]. In a meta-analysis 
including 7,500 Han Chinese [244], the ACE DD genotype 
was associated with higher risk of stroke (OR[95%CI]=1.91 
[1.56-2.34). In a meta-analysis involving 1121 patients with 
preeclampsia and 1361 controls from 11 studies [245], the 
ACE DD genotype was associated with increased risk of 
preeclampsia (OR[95%CI]=1.51 [1.17-1.94). 
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ACE and Renal Function 
 A meta-analysis of 42 studies including 13,000 
participants (published between 1994 and 2010) reported an 
association between the ACE I/D polymorphism and diabetic 
nephropathy [246]. The ACE D allele was associated with 
increased risk of diabetic nephropathy (OR[95%CI]=1.24 
[1.12-1.37]) [246]. This was also true for subgroup analysis 
in type 1 nephropathy, type 2 nephropathy, ESRD and 
proteinuria [246]. When stratifying by ethnic group, this 
association was only observed in Asians and not in 
Caucasians [246]. The ACE I/D polymorphism therefore 
appears to be a useful test to predict the progression of type 1 
or type 2 diabetic nephropathy [247].  
 The role of the ACE I/D polymorphism in non-diabetic 
renal disease is less well established [247]. In 2847 
participants to the MESA study, the ACE I/D polymorphism 
was not associated with renal function [248]. The ACE locus 
did not come out from large scale genome-wide meta-
analyses of renal function or CKD [44, 140, 141]. In a meta-
analysis, the ACE I/D polymorphism was not associated with 
ESRD or risk of hypertension in patients with autosomal 
dominant polycystic kidney disease [249]. The ACE D allele 
was also associated with increased risk of minimal change 
nephritic syndrome in Asians (OR [95%CI]=1.38[1.07-
1.79]) [50]. In a meta-analysis including 11 studies [250], the 
ACE DD genotype was associated with susceptibility to, and 
progression of, IgA nephropathy with stronger associations 
in Asians than in Caucasians.  
ACE and Salt-sensitivity 
 Only few studies have analyzed the association between 
the ACE I/D polymorphism and blood pressure salt-
sensitivity. Hypertensive patients carrying the II genotype 
had higher ambulatory blood pressure increase under high 
salt intake than patients carrying the DD genotype [251]. In 
this study [251], the ACE I allele was therefore associated 
with higher salt-sensitivity than the D allele. This is in line 
with one study including 66 hypertensive patients in Japan 
[252] and with a study including 71 hypertensive patients  
in Spain [253], whereas other Japanese studies including  
104 [254] and 188 [255] hypertensive patients found no  
such association. Although large scale studies are needed  
to confirm this, it seems that the I allele of the ACE I/D 
polymorphism confers blood pressure sensitivity to salt 
intake. 
ACE and Pharmacogenetics 
 In an overview published in 2006, Arnett et al. identified 
11 studies having analyzed the role of the ACE I/D 
polymorphism on blood pressure response to ACE inhibitor 
treatment, but the results were inconsistent [256]. In 
particular, the ACE I/D polymorphism was not associated 
with blood pressure response to ACE inhibitor (perindopril) 
treatment, or with the long-term risk of stroke and cardiac 
events, in 5,688 participants to the PROGRESS trial [257]. 
In a study including 208 Finnish hypertensive men, the ACE 
I/D polymorphism did not influence blood pressure response 
to treatment [258]. In the large scale GenHAT study 
including data on 37,000 people, the ACE I/D polymorphism 
did not significantly predict fatal and nonfatal coronary heart 
disease, myocardial infarction, stroke or all-cause mortality 
[259]. Similary, in 8907 patients with stable coronary artery 
disease from the EUROPA trial [260], the ACE I/D poly- 
morphism was not associated with ACE inhibitor treatment 
benefit (i.e. no association with cardiovascular morbidity and 
mortality during follow-up). By contrast, in this same study, 
ACE inhibitor treatment benefit was associated with variants 
in the AT1 receptor and BK1 receptor genes [260]. These 
results suggest that the ACE I/D polymorphism is unlikely to 
be clinically relevant in predicting response to antihyper- 
tensive treatment or risk of cardiovascular disease in the 
absence of renal dysfunction. 
 The situation is quite different in the presence of renal 
dysfunction or in the presence of high salt intake [247]. 
Multiple lines of evidence suggest that the ACE DD 
genotype is associated with reduced renal benefit from ACE 
inhibitor treatment in patients with type 1 or type 2 diabetic 
nephropathy [247, 261]. In 1435 type 2 diabetic patients with 
nephropathy, who participated to the RENAAL study, the 
ACE D allele was associated with poor renal prognosis in the 
placebo group, whereas no such association was found in the 
losartan group, which suggests that losartan was able to 
correct the poor prognosis associated with the ACE D allele 
[262]. Patients carrying the DD genotype respond less well 
to ACE inhibitor treatment under conditions of high salt  
diet [263]. In 27 healthy subjects, angiotensin I infusion  
led to higher blood pressure, renal vascular resistance, and 
aldosterone levels in those carrying the DD genotype than in 
those carrying the ID and II genotypes under liberal sodium 
intake, but not under low sodium intake [264]. Similar 
results were obtained in type 1 diabetic patients [265]. These 
results are compatible with a gene-environment interactions 
between the ACE I/D polymorphism and dietary sodium 
intake for their effects on blood pressure and renal function. 
 In summary, ACE is an enzyme involved in the renin-
angiotensin-aldosterone and kinin-kallikrien pathways 
involved in blood pressure control. ACE inhibitors are used 
to treat cardiovascular and renal diseases, including hyper- 
tension. The high inter-individual variability in circulating 
ACE levels is explained, in large part, by the ACE I/D 
polymorphism. The D allele of the ACE I/D polymorphism is 
clearly associated with increased risk of diabetic nephro- 
pathy. By contrast, the associations of the ACE I/D 
polymorphism with hypertension and cardiovascular disease 
have been inconsistent. The ACE I/D polymorphism is a 
useful test to predict the renoprotective effect of ACE 
inhibitor or angiotensin receptor blocker treatment in 
patients with kidney disease [247]. There is currently no 
evidence to support a role of the ACE I/D polymorphism in 
predicting future risk of cardiovascular events or blood 
pressure response to ACE inhibitors in the absence of renal 
dysfunction.  
2.4.2. MTHFR Gene 
 MTHFR is located on chromosome 1p36.22 and encodes 
the methylenetetrahydrofolate reductase. This enzyme is a 
key enzyme for folate homeostasis and catalyzes the con- 
version of 5,10-methylentetrahydrofolate to 5-methyltetra- 
hydrofolate, the substrate for the conversion of homocysteine 
to methionine [266]. The latter is involved in the methylation 
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of DNA and proteins. MTHFR includes 11 exons [267] and 
several (>60) polymorphisms have been identified. Some  
of them are nonsynonymous polymorphisms and alter  
the protein product. For example, C677T (rs1801133) and 
A1298C (rs1801131) are associated with decreased MTHFR 
activity and increased homocysteine levels [268]. 
 MTHFR genetic variations cause MTHFR deficiency, 
neural tube defects and some evidence suggests an associa- 
tion with cancer [269]. Severe deficiency in MTHFR causes 
elevated homocysteine concentrations, an atherothrombotic 
sulfur amino acid associated with increased risk of cardio- 
vascular disease [270]. Meta-analyses on the associations 
between MTHFR genotype and coronary heart disease have 
provided conflicting results [271]. These analyses allow 
testing a causal role of elevated homocysteine concentrations 
while avoiding bias from reverse causation given the 
principle of mendelian randomization.  
MTHFR, Homocysteine and Kidney Function 
 CKD patients and to a major extend patients on dialysis 
suffered from elevated homocysteine [272], which may 
explain a large proportion of the attributable mortality of 
CKD [273]. MTHFR polymorphisms have been associated 
with an increased risk of ESRD [274] and increased risk of 
cardiovascular risk in ESRD [275]. 
 Data on the association between MTHFR and CKD 
patients at an earlier stage of ESRD are also available. 
MTHFR variants have been associated with accelerated 
chronic decline in renal function. The influence of MTHFR 
variants C677T and A1298C on progressive loss of kidney 
function has been analyzed in 821 African-Americans with 
hypertensive nephrosclerosis from the longitudinal National 
Institute of Diabetes and Digestive and Kidney Diseases 
African-American Study of Kidney Disease and Hyper- 
tension (AASK) Trial [276]. In this study, the A1298C 
variant predicted the rate of GFR decline. A1298/A1298 
major allele homozygosity resulted lower decline of GFR. 
Subjects with A1298/A1298 had a decline of 0.034 
mL/min/1.73 m2/week versus 0.048 and 0.042 mL/min/1.73 
m2/week in heterozygotes and 1298C/1298C subjects, 
respectively [276]. This result was replicated in an 
independent follow-up study (San Diego VAHC study). 
C677T alone did not show an individual effect. The relation- 
ship of MTHFR gene polymorphisms with the presence and 
the severity of renal disease was investigated in 100 patients 
with CKD and 120 healthy controls Tunisians. C677T and 
A1298C polymorphisms were not associated with the 
presence of non-ESRD renal disease [277]. In a substudy of 
677 patients with ESRD using dialysis (N=213) or advanced 
CKD (N=464) in the Homocysteinemia in Kidney and End-
Stage Renal Disease [HOST] trial, the C677T genotype 
frequencies, but not A1298C, differed between patients with 
ESRD and those with advanced CKD [278]. Frequencies of 
the C677T CC, CT, and TT genotypes were 62%, 32%, and 
7% in participants with ESRD and 54%, 35%, and 11% in 
participants with advanced CKD, respectively (P =0.03). 
This study also examined the mortality associated with 
MTHFR genotypes. In patients with ESRD with the mutant 
C677T TT genotype, the adjusted hazard ratio for mortality 
was 2.27 (95%CI 1.07-4.84; P = 0.03). The relationship was 
not significant in patients with advanced CKD. The overall 
relationship between the A1298C polymorphism and 
mortality was significant neither in patients with ESRD nor 
in patients with advanced CKD [278]. Studies conducted in 
other populations (e.g., Cyprus [279], Poland [280]) reported 
association between MTHFR variants and the risk of CKD. 
However, the MTHFR region was not uncovered as 
associated with CKD or other renal traits in recent GWAS 
[43, 44, 141]. 
 Some of the mechanisms by which MTHFR mutations 
influence kidney function are possibly mediated by homo- 
cysteine. Elevated levels of homocysteine are associated 
with increased risk of thrombosis and MTHFR genetic 
variants are associated with inherited thrombophilia states 
[281]. Patients with inherited thrombophilia experience 
chronic thrombotic events including within the renal 
vasculature, which can result in gradual and progressive 
decline in renal function. The association of MTHFR C677T 
polymorphism with renal vascular sclerosis was compared 
between patients whose renal biopsies showed vascular 
disease (diabetic patients, hypertensive patients, diabetic and 
hypertensive patients, smokers, and idiopathic renal disease) 
and patients without vascular sclerosis at the biopsy [281]. In 
34 patients with diabetes, hypertension, or both, there was no 
significant difference compared to the controls. However, in 
17 patients with idiopathic vascular disease group, MTHFR 
C677T mutant polymorphism was associated with vascular 
sclerosis (29.4% in patients with idiopathic vascular disease 
versus 4% in controls, p value=0.03). These results suggest 
that patients without hypertension and diabetes but with 
idiopathic renal vascular disease might be predisposed to 
vascular scarring by thrombophilic gene mutations [281]. 
The atherothrombotic propriety of homocysteine potentially 
mediates the increased risk of vascular sclerosis and  
kidney failure. Some reports have indeed linked higher 
homocysteine levels to a greater decline of GFR [282], while 
others did not [283, 284] and the ultimate origin and 
pathophysiology for elevated homocysteine levels in kidney 
failure are still unclear [285].  
 The comparison of the relationship between MTHFR, 
homocysteine and kidney function across different settings 
can also be confounded by other environmental factors  
such as folic acid intake and fortification policy. MTHFR 
C677T is especially associated with moderate elevated 
homocysteine concentration in setting of marginal folate 
intake [286].  
MTHFR, Homocysteine and Blood Pressure 
 Contrary to some of the other pharmacogenes discussed 
in this review, associations between MTHFR and blood 
pressure were already suggested before associations from 
GWAS on blood pressure and hypertension were available. 
For example, in 2004, a meta-analysis of studies comparing 
women with and without hypertension in pregnancy for the 
MTHFR C677T suggested that the T allele increases the risk 
of severe diastolic hypertension during pregnancy [287]. 
Nevertheless, important insights emerged from the GWAS. 
The MTHFR region has been uncovered as a loci associated 
with blood pressure or hypertension in multiple GWAS. A 
GWAS was conducted in 18,738 Caucasian women who 
participated in the Women’s Health Study cohort study  
and were free of hypertension at baseline. blood pressure 
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progression at 48 months and incident hypertension during 
the entire follow-up according to the different genotypes 
were assessed [288]. MTHFR rs1801133 had a significant 
association with blood pressure progression. The OR for 
blood pressure progression (95%CI) for MTHFR rs1801133 
(minor allele T) was 1.05 (1.00–1.10), but this association 
nor the association with incident hypertension remain 
significant after adjustment for multiple testing [288].  
 Analyses from the GlobalBPGen and CHARGE 
consortia data showed an association between systolic or 
diastolic blood pressure and variant (rs17367504) near the 
MTHFR gene (P=2 x 10
-13
) in the MTHFR/CLCN6/NPPB 
locus. Carriers of the G allele at this polymorphism were less 
likely to have hypertension compared to carriers of the A 
allele (OR 0.89, 95%CI 0.86-0.93, p value 2 x 10
-9
). The 
rs17367504 is located in an intron of the MTHFR gene but in 
a region with many plausible candidate genes, including 
MTHFR, CLCN6, NPPA, NPPB and AGTRAP [47]. Signal 
near the MTHFR gene was also uncovered in a recent 
GWAS conducted in Chinese Hans, but the association was 
limited to diastolic blood pressure [52]. Significant 
association with systolic blood pressure was replicated for 
MTHFR rs17367504 (beta coefficient: 0.65, p value= 0.03) 
among Japanese subjects (N=1526) [289]. 
 The MTHFR region was also identified in the first  
large-scale (N=2020) experiment using the new Illumina 
HumanCVD BeadChip (50K IBC array) in relation to mean 
24-hour systolic and diastolic blood pressure (GRAPHIC 
Study) [290]. A strong association between rs13306560 
polymorphism in the promoter region of MTHFR and 
CLCN6 and mean 24-hour diastolic blood pressure was 
found. Each minor allele of rs13306560 was associated with 
2.6 mm Hg lower mean 24-hour diastolic blood pressure 
(P=1.2108). Interestingly, this study also showed that a 
majority of the candidates previously associated with clinical 
measurements of blood pressure were not or only weakly 
associated with mean 24-hour blood pressure. The investi- 
gators stressed that mean 24-hour blood pressure has a 
higher heritability than clinic measurements and is probably 
more informative in gene discovery [290]. Unfortunately, the 
number of studies with data on both high-throughput genetic 
and 24-hour blood pressure information is currently too 
limited to replicate such analysis on a sufficient large scale.  
 While this study further suggests that MTHFR gene is a 
causal gene for hypertension, it is worth noting that some 
recent candidate gene studies and GWAS did not replicate 
the association. For example, MTHFR gene polymorphisms 
C677T and A1298C were not risk factors for hypertension in 
a recent candidate gene study conducted among 150 Turkish 
participants [291] and this signal was absent in a GWAS of 
Korean cohorts [292].  
 The influence of MTHFR polymorphisms on blood 
pressure and hypertension could again be mediated, at least 
in part, by homocysteine. Homocysteine levels have been 
associated with hypertension and the different mechanisms 
leading to hyperhomocysteinemia-associated hypertension 
have recently been reviewed [293]. Mechanisms include 1) 
activation of metalloproteinases with reduction of vascular 
elastance, 2) reduction of H2S production, a strong anti- 
oxidant and vasorelaxation factor, and 3) alteration of the 
physiological balance between the NO/endothelin system, 
which is responsible for vasodilation/vasoconstriction and 
remodelling processes of the vasculature. There is however 
some evidence that mild elevated homocysteine can not 
solely explain the hypertensive risk associated to MTHFR 
genotype. In a case-control study of 458 participants, an 
increased hypertensive risk was observed in MTHFR C677T 
TT carriers men with homocysteine level higher than 15 
micromol/L (OR=2.78; 95%CI 1.05-7.3, p value=0.03) but 
not in those non-TT carriers men with homocysteine level 
higher than 15 micromol/L (p value=0.33) [294]. 
 The pharmacogenomics of MTHFR in general has been 
reviewed elsewhere [266]. Below, we discuss the 
pharmacogenomics of MTHFR related to blood pressure. We 
identified studies that did investigate the modification of the 
association between benazepril treatment (an ACE inhibitor) 
and blood pressure by MTHFR C677T. In 2005, Jiang S  
et al. investigated in Chinese hypertensive patients whether 
short-term blood pressure response to benazepril, was 
modulated by haplotypes re-constructed from both C677T 
and A1298C polymorphisms in MTHFR gene [295]. A total 
of 410 hypertensive patients recruited from 344 nuclear 
families were treated orally with benazepril at a daily dosage 
of 10 mg for 15 consecutive days. Blood pressure was 
measured at baseline and on the 16th day of treatment. The 
individuals carrying one copy of haplotype 677C-1298C had 
significantly lower diastolic and systolic blood pressure 
response to benazepril treatment (beta coefficient=-1.9, p= 
0.003 and beta coefficient =-2.9, p =0.043, respectively), in 
comparison to those without this haplotype. In 2011, the 
same group conducted a similar study, yet without haplotype 
analysis, but in a larger Chinese population (N=823). 
MTHFR C677T was associated with baseline systolic blood 
pressure (beta coefficient=2.84, P=0.0096) and baseline 
diastolic blood pressure (beta coefficient=2.19, P=0.0008). 
MTHFR C677T was independently associated with increased 
diastolic blood pressure response (baseline minus post-
treatment) to benazepril treatment (beta coefficient =1.58, 
P=0.038), but not with systolic blood pressure response 
[296]. Thus, MTHFR C677T polymorphisms may modify 
some of the blood pressure response to benazepril treatment.  
 Vitamin B12, B6, and B2 (riboflavin) are the main 
nutritional determinants of homocysteine. Intervention 
studies based on vitamin B supplementation have generally 
reported no effect on blood pressure. As Wilson et al. 
discussed elsewhere, studies have rarely considered the 
MTHFR C677T polymorphisms [297]. One study did 
examine the effect of riboflavin (1.6 mg/day for 16 weeks) 
on blood pressure by MTHFR C677T polymorphism in 181 
premature cardiovascular disease patients [298]. Among 
patients taking one or more antihypertensive drugs at 
recruitment, the target blood pressure (<140/90 mmHg) was 
achieved in only 37% patients with the TT genotype 
compared with 59% with the CT and 64% with the CC 
genotype (P < 0.001). Riboflavin intervention reduced mean 
blood pressure specifically in those with the TT genotype 
(from 144/87 to 131/80 mmHg; P < 0.05 systolic; P < 0.05 
diastolic), with no response observed in the other genotype 
groups [298]. Williams et al. conducted an intervention 
study where 41 asymptomatic men with normal or high-
normal ambulatory blood pressure were randomized to 
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receive in a placebo-control, cross over study, 3 weeks of 5 
mg folic acid/day or placebo. The investigators found a 
similar blood pressure response (decrease) to folate 
supplementation across MTHFR C677T genotypes [299]. It 
is worth noting that MTHFR genotypes have also been 
associated with risk of dyslipidemia and diabetes [300-302]. 
MTHRF and Salt-sensitivity 
 We could not identify studies addressing salt sensitivity 
and MTHFR. We suggest therefore that this is an area in 
need of further research investment. MTHFR is a key 
enzyme in folate and homocysteine metabolism. Selected 
MTHFR genetic variants cause MTHFR deficiency and  
are associated with neural tube defects and inherited 
thrombophilia states. Patients with impaired renal function 
have elevated homocysteine concentrations, and MTHFR 
polymorphisms have been associated with the risk of 
developing ESRD. In recent GWAS, the MTHFR locus was 
associated with blood pressure and/or hypertension, but not 
with renal function or CKD. As other plausible nearby blood 
pressure candidate genes exist (e.g., NPPA, NPPB) further 
studies are needed to determine whether MTHFR is indeed 
the causal gene. Homocysteine seems to explain only 
partially the associations between MTHFR polymorphisms 
and kidney function and blood pressure/hypertension. Some 
studies showed that MTHFR variants significantly modified 
the blood pressure response to antihypertensive drugs. 
CONCLUSIONS AND OUTLOOK 
Top Three Pharmacogenomic and Personalized Medicine 
Applications in Renal Pharmacogenomics: A Strategic 
Agenda 
 Pharmacogenes have been mostly studied for their effects 
on drug metabolism, safety and efficacy. Less is known on 
the roles of pharmacogenes in disease susceptibility or 
kidney pathophysiology. More specifically, we consider that 
the role of pharmacogenes for endogenous substrates in 
relation to renal function and blood pressure needs more in-
depth investigation. While the genome-wide meta-analyses 
(GWAS) have not identified the VIP pharmacogenes as 
being robustly associated with renal function, these initial 
explorations do not necessarily address the entire genetic 
variability of renal function or blood pressure (so-called 
“missing heritability”). CKD is a growing public health 
burden worldwide and a better understanding of its 
pathophysiology is urgently needed, as are new therapeutic 
interventions. As illustrated in this paper, a substantial 
number of important pharmacogenes are associated with 
blood pressure and hypertension in humans. With the 
exception of VDR, the link with renal function is less clear, 
but this has been under-studied so far. Further studies are 
needed in this area because 1) the kidney is the major organ 
responsible for blood pressure control, and 2) renal function 
is an important determinant of the clearance of many drugs 
and other xenobiotics. This knowledge is important to better 
assess the role of pharmacogenes in health in general and to 
individualize treatment in particular.  
 In our view, ACE inhibitors represent the first pharma- 
cogenomic application at the nexus of renal pathophysiology 
and cardiovascular medicine. As detailed in this paper,  
ACE inhibitor treatment is clearly renoprotective. Further- 
more, the ACE I/D polymorphism is a useful test to predict 
the progression of type 1 or type 2 diabetic nephropathy 
[247] and also to predict benefit from ACE inhibitor 
treatment.  
 Among the selected pharmacogenes, two are nuclear 
receptors, namely VDR and PXR. The role of nuclear 
receptors in renal diseases has been recently highlighted with 
an emphasis on carbohydrate metabolism, lipid metabolism, 
immune response and inflammation[208]. We here add a 
new putative link between nuclear receptors and renal 
diseases, namely via blood pressure control and renal sodium 
handling (Fig. 1). Lipid and drug metabolisms are also 
tightly interconnected via shared regulation by nuclear 
receptors such as PXR, CAR, VDR and GR [303]. PXR was 
originally described as a xenobiotic sensor, but it is now 
being increasingly recognized as an endobiotic sensor with 
roles in modulating inflammation as well as lipid, energy and 
vitamin D metabolisms [211]. We here put forward the 
hypothesis that PXR may also play a role in blood pressure 
control and renal sodium handling via its action on the 
transcription of the ABCB1 and CYP3A5 genes. For the other 
nuclear receptor, VDR, the link with blood pressure and 
renal function, in particular, is clear, as previously 
mentioned. We therefore choose VDR agonists, such as 
vitamin D analogs, as our second pharmacogenomic applica- 
tion at the nexus of renal pathophysiology and cardio- 
vascular medicine. 
 Several dietary factors may influence the expression and 
activity of pharmacogenes, among which grapefruit juice and 
herbal extracts such as St John’s wort stand out [95]. Dietary 
salt has been found to modulate quinidine and verapamil 
disposition, but only in case of oral administration [93, 94], 
which suggests that the influence of salt intake on gene 
expression is tissue-specific [95]. Recent data in mice 
showed that dietary salt intake influence the expression of 
several pharmacogenes, namely CYP3A genes, ABCB1 and 
PXR, and that this effect is tissue specific [95]. More studies, 
including human studies, are needed to explore the role of 
dietary salt intake on the expression and action of pharma- 
cogenes. The kidney is responsible for salt homeostasis. 
Although large inter-individual differences in the blood 
pressure response to salt intake exist, selected subgroups 
appear to be more salt-sensitive than others. In particular, 
high salt intake is known to increase blood pressure in 
elderly people, people of African descent and patients with 
hypertension, obesity or CKD. A large body of evidence 
suggests that reducing salt intake lowers blood pressure and 
reduces risk of cardiovascular disease [304-306]. Low salt 
intake is expected to be of particular benefit to patients with 
hypertension or reduced kidney function. So far, data on the 
genetic determinants of blood pressure sensitivity to salt are 
limited and results have been inconsistent [34, 307]. Among 
the reasons to explain these discrepancies, we can mention 
the fact that currently used protocols substantially vary 
across studies (e.g., one-week low salt versus one-week high 
salt, response to i.v. NaCl infusion, response to an i.v. 
diuretic dose, etc). Furthermore, as these research protocols 
are quite demanding, sample sizes have usually been very 
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small, with rarely more than 100 participants, so that studies 
have been underpowered to detect small effect sizes. We are 
therefore lacking a salt-sensitivity test suitable for large scale 
population-based studies. Baring these limitations in mind, 
several pharmacogenes are currently considered as being 
salt-sensitivity genes (Fig. 1). Yet, we know little on the role 
of dietary salt intake on the expression of these pharma- 
cogenes. Furthermore, little has been done to explore the  
role of salt intake on the pharmacokinetics and pharma- 
codynamics of drugs in general and, of drugs used to treat 
essential arterial hypertension and renal dysfunction in 
particular. If salt intake plays an important role, this may 
have clinical consequences in adapting drug doses to achieve 
better treatment safety and efficiency, while maintaining 
optimal preventive strategy to reduce overall cardiovascular 
risk. We therefore choose ‘reduced dietary salt-intake’ as our 
third pharmacogenomic application at the nexus of renal 
pathophysiology and cardiovascular medicine for its 
potential to reduce cardiovascular risk in salt-sensitive 
individuals.  
 As previously suggested [308], we support that idea that 
randomized controlled trials should systematically include 
in-depth genotyping of participants, at least for important 
pharmacogenes to allow exploring inter-individual variability 
in drug response as well as gene-gene interactions in large 
samples.  
 As some of the pharmacogenes also act as xenobiotic 
sensors, multiple interactions between genes, drugs as well 
as other xenobiotics and dietary factors are expected. This 
underscores the need for large-scale international consortia 
to decipher the complex interplay between xenobiotics, 
endobiotics and pharmacogenes on kidney function and 
diseases in humans. 
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ABCB1 = ATP-binding cassette, subfamily B (MDR/ 
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ACE = Angiotensin converting enzyme 
ACEI = Angiotensin converting enzyme inhibitors 
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CYP1A2 = Cytochrome P450, family 1, subfamily A, 
polypeptide 2 
CYP3A5 = Cytochrome P450, family 3, subfamily A, 
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ESRD = End-stage renal disease 
GFR = Glomerular filtration rate 
GWAS = Genome-wide association studies 
MTHFR = Methylenetetrahydrofolate reductase (NAD 
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PXR = Pregnane X receptor 
VDR = Vitamin D receptor 
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